SciELO - Scientific Electronic Library Online

 
vol.145 issue1Origin, components and mechanisms of action of the Mediterranean dietEpidemiological analysis of breast cancer mortality in women in Chile author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista médica de Chile

Print version ISSN 0034-9887

Abstract

HERNANDEZ-ROCHA, Cristian et al. Management of severe ulcerative colitis: An up-to-date. Rev. méd. Chile [online]. 2017, vol.145, n.1, pp.75-84. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872017000100013.

Ulcerative Colitis (UC) is a chronic inflammatory disease involving the colon, with alternating periods of remission and activity. Exacerbations can be severe and associated with complications and mortality. Diagnosis of severe UC is based on clinical, biochemical and endoscopic variables. Patients with severe UC must be hospitalized. First line therapy is the use of intravenous corticoids which achieve clinical remission in most patients. However, 25% of patients will be refractory to corticoids, situation that should be evaluated at the third day of therapy. In patients without response, cytomegalovirus infection must be quickly ruled out to escalate to second line therapy with biological drugs or cyclosporine. Total colectomy must not be delayed if there is no response to second line therapy, if there is a contraindication for second line therapies or there are complications such as: megacolon, perforation or massive bleeding. An active management with quick escalation on therapy allows to decrease the prolonged exposure to corticoids, reduce colectomy rates and its perioperative complications.

Keywords : Colitis, Ulcerative; Colonic Diseases; Drug Therapy; Inflammatory Bowel Diseases.

        · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License